Ariad CEO says Italy and Spain likely to pay for new cancer drug - Boston Globe

Ponatinib would compete with Bristol-Myers Squibb Co.’s Sprycel, also known as dasatinib, and Novartis AG’s Tasigna, if it’s approved by regulators. Ariad, based in Cambridge, plans to present the data to be submitted to regulators from a ...

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

Treatment with SPRYCEL® (dasatinib) can cause severe (NCI CTC Grade 3/4) thrombocytopenia, neutropenia, and anemia, occurring more frequently in advanced phase CML or Ph+ ALL than in chronic phase CML. Myelosuppression was reported in patients ...

Generic floodgates open for Plavix in U.S. - FiercePharma

They were encouraged by growing sales of some new drugs in the first quarter, including cancer drug Yervoy, hepatitis B drug Baraclude, and Sprycel, a drug for chronic myeloid leukemia, which posted a 34% gain to $231 million. Teva, Mylan ...

4 Large Cap Dividend Stocks With Strong Profits That Analysts Rate As Buy - Seekingalpha.com

The company's principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in adults ...

BUYINS.NET: Market Maker Surveillance Report. MS, T, JPM, BMY, … - TMCnet

The companys principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in ...

Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - msnbc.com

Dasatinib (Sprycel), Docetaxel (Taxotere), Dovitinib, Doxorubicin liposomal (Doxil), Eribulin (Halaven), Erlotinib (Tarceva), Everolimus (Afinitor), Exemestane (Aromasin), Fadrozole (Afema), Fluoxymesterone, Fulvestrant (Faslodex), Ganitumab ...

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seekingalpha.com

Data on Anti-PD-1 BMS-936558 to be highlighted in ASCO press briefing on Friday, June 1 at 3:00 PM CT. Long-term follow-up data on SPRYCEL (dasatinib) in patients with chronic-phase CML resistant or intolerant to Gleevec to be presented. The details of the ...